ANDROCAN研究最终结果:局限性前列腺癌术前性腺状态相关的组织病理学特征与术后5年生化复发
ANDROCAN是一项前瞻性队列研究,纳入1318例接受根治性前列腺切除术的局限性前列腺癌患者,随访5年。结果显示237例出现生化复发,复发与基线Gleason评分、PSA水平及pT>3a正相关,而术前总睾酮和生物可利用睾酮水平与生化复发无关。
要点
- 基线Gleason评分、PSA水平和pT>3a与生化复发正相关,而总睾酮和生物可利用睾酮水平与生化复发无关。
- 生化复发患者较无复发者基线Gleason评分更高(p=0.0001)、PSA值更高(p=0.0005)。
- 术前生化性性腺功能减退与术后5年内生化复发风险升高无关。
核心结论
- PSA水平、高Gleason评分和pT>3a与初始治疗后疾病复发可能性更高相关,可作为预测生化复发风险的重要预后指标。
- 在这项前瞻性研究中,生化性性腺功能减退与前列腺切除术后5年内生化复发发生率升高无关。
- 术前患者的生物学性腺状态可能对治疗决策有用,但不提供肿瘤学随访的指征。
研究设计与样本
- 前瞻性队列研究,纳入1318例接受根治性前列腺切除术的局限性前列腺癌患者,术后随访5年。
- 术前基线采集临床和激素数据(总睾酮、生物可利用睾酮、双氢睾酮、雌酮和雌二醇,采用气相色谱/质谱法测定)及代谢综合征参数。
- 病理数据(主要Gleason 4级和分期)集中收集并交叉核对;采用多因素分析评估与生化复发相关的因素,Kaplan-Meier分析评估无生化复发生存。
主要发现
- 1318例患者中237例出现生化复发。
- 生化复发患者与无生化复发患者的人口学特征相似,但生化复发患者基线Gleason评分更高(p=0.0001)、PSA值更高(p=0.0005)。
- Gleason评分、pT>3a和基线PSA水平与生化复发正相关(分别为p<0.0001、p<0.0001、p=0.0048),而生物可利用睾酮和总睾酮水平与生化复发无关。
关键数值与推荐
- Gleason评分与生化复发正相关(p<0.0001)。
- pT>3a与生化复发正相关(p<0.0001)。
- 基线PSA水平与生化复发正相关(p=0.0048)。
- 生物可利用睾酮和总睾酮水平与生化复发无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究纳入具有不同临床特征(如肿瘤病史和代谢综合征)的患者,引入变异性,使得难以分离性腺状态对生化复发的特定影响。
- 缺乏5年以上长期生化复发的评估,可能遗漏术后5至15年间发生的复发,可能导致对实际长期复发率的低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Failure rates after first-line treatment of localized prostate cancer (PCa) treatment remain high; therefore, it is essential to improve the selection and identification of at-risk patients to reduce mortality. The aim of the ANDROCAN study was to evaluate the biochemical recurrence (BCR) in patients with localized PCa treated by total prostatectomy at 5 yr after surgery, according to their presurgery gonadal status. METHODS: A prospective cohort study was conducted including 1318 patients undergoing total prostatectomy for localized PCa with a 5-yr postoperative follow-up. Clinical and hormonal data (assays of total testosterone [TT], bioavailable testosterone [BT], dihydrotestosterone, estrone, and estradiol were performed by gas chromatography/mass spectrometry) as well as metabolic syndrome parameters were collected at baseline before surgery. Pathological data (predominant Gleason grade 4 and stage) were collected and cross-referenced centrally. Factors associated with BCR were assessed by a multivariate analysis, and BCR-free survival was assessed by a Kaplan-Meier analysis. KEY FINDINGS AND LIMITATIONS: Among the 1318 patients, 237 had BCR of PCa. Considering demographic characteristics, populations with and without BCR were similar. However, patients with BCR had cancers with a higher Gleason score (p = 0.0001) and higher prostate-specific antigen (PSA) values (p = 0.0005) at baseline. Gleason score, pT >3a, and PSA level at baseline were positively correlated with BCR (p < 0.0001, p < 0.0001, and p = 0.0048, respectively), while BT and TT levels were not associated with BCR. This study includes patients with varying clinical characteristics, such as cancer history and metabolic syndrome, introducing variability that makes it challenging to isolate the specific effects of gonadal status on BCR. Another limitation is the lack of evaluation of long-term BCR beyond 5 yr, potentially overlooking recurrences that occur between 5 and 15 yr after surgery. This could lead to an underestimation of the actual long-term recurrence rates. CONCLUSIONS AND CLINICAL IMPLICATIONS: Overall, PSA levels, high Gleason score, and pT >3a are associated with a greater likelihood of disease recurrence following initial treatment and could serve as important prognostic indicators for predicting the risk of BCR. In this prospective study, biochemical hypogonadism was not associated with a higher occurrence of BCR within 5 yr of prostatectomy. The biological gonadal status of preoperative patients could potentially be useful for therapeutic decisions but does not provide an indication for the oncological follow-up. PATIENT SUMMARY: Five-year follow up of patients after surgery showed that there is no association between hypogonadism (low levels of total testosterone and bioavailable testosterone) and cancer recurrence. However, cancer recurrence seems to be more associated with aggressiveness of cancer at the time of detection.
引用
- Neuzillet Y, Raynaud JP, Dreyfus JF, et al. Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal Status. Eur Urol Oncol. 2024. PMID: 39209681. doi:10.1016/j.euo.2024.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。